ArticleGynecologic oncology reports2025
Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Guillain-Barré syndrome (GBS) is a rare yet potentially life-threatening adverse event of immune checkpoint inhibitors (ICI). It classically presents with ascending symmetric weakness, areflexia, and distal sensory loss. We present a case of pembrolizumab-induced GBS in a patient with advanced endometrial cancer. Methods: All information was obtained via chart review with patient consent. Results: A 77-year-old female with stage IIIC1 grade 3 endometrioid endometrial cancer received received carboplatin, paclitaxel, and pembrolizumab. After 5 cycles, she developed progressive bilateral lower-extremity paresthesias, sensory loss, areflexia, and distal weakness. Lumbar puncture demonstrated albuminocytologic dissociation, and electromyography confirmed acute inflammatory demyelinating polyneuropathy. Pembrolizumab was discontinued, and the patient received intravenous immunoglobulin with improvement. Conclusion: This case highlights the importance of early recognition of GBS. ICI discontinuation and rapid initiation of treatment are essential to avoid life-threatening complications and optimize patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.